These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12062539)

  • 1. High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention.
    ten Berg JM; Gerritsen WB; Haas FJ; Kelder HC; Verheugt FW; Plokker HW
    Thromb Res; 2002 Mar; 105(5):385-90. PubMed ID: 12062539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment with oral anticoagulants decreases platelet activation in patients before and after percutaneous coronary intervention.
    ten Berg JM; Gerritsen WB; Haas FJ; Kelder JC; Verheugt FW; Thijs Plokker HW
    Thromb Haemost; 2002 Dec; 88(6):924-30. PubMed ID: 12529740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?
    Hézard N; Metz D; Nazeyrollas P; Droullé C; Potron G; Nguyen P
    Thromb Res; 2002 Oct; 108(1):43-7. PubMed ID: 12586131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.
    Gulmez O; Yildirir A; Kaynar G; Konas D; Aydinalp A; Ertan C; Ozin B; Muderrisoglu H
    J Thromb Thrombolysis; 2008 Jun; 25(3):239-46. PubMed ID: 17574519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty.
    Ciabattoni G; Ujang S; Sritara P; Andreotti F; Davies G; Simonetti BM; Patrono C; Maseri A
    J Am Coll Cardiol; 1993 May; 21(6):1377-81. PubMed ID: 8473644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention.
    Chiu FC; Wang TD; Lee JK; Shih FY; Lin JW; Huang CH; Chen WJ; Chen MF
    Eur J Intern Med; 2011 Oct; 22(5):471-7. PubMed ID: 21925055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.
    Bilsel T; Akbulut T; Yesilcimen K; Terzi S; Sayar N; Dayi SU; Akgoz H; Ergelen M; Ciloglu F
    Heart Vessels; 2006 Mar; 21(2):102-7. PubMed ID: 16550311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures.
    Gregorini L; Marco J; Fajadet J; Bernies M; Cassagneau B; Brunel P; Bossi IM; Mannucci PM
    J Am Coll Cardiol; 1997 Jan; 29(1):13-20. PubMed ID: 8996289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effects of post coronary stenting triple antiplatelet therapies on platelet functions].
    Han YL; Su QF; Li Y; Kang J; Yan CH; Wang SL
    Zhonghua Nei Ke Za Zhi; 2006 Aug; 45(8):635-8. PubMed ID: 17074146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of platelet inhibition of ticlopidine plus aspirin vs aspirin alone given prior to elective PTCA.
    van de Loo A; Nauck M; Noory E; Just H; Wollschläger H
    Eur Heart J; 1998 Jan; 19(1):96-102. PubMed ID: 9503181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets.
    Würtz M; Grove EL; Wulff LN; Kaltoft AK; Tilsted HH; Jensen LO; Hvas AM; Kristensen SD
    JACC Cardiovasc Interv; 2010 Aug; 3(8):828-35. PubMed ID: 20723855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty.
    Wilson AM; Brittenden J; Bachoo P; Ford I; Nixon GF
    J Vasc Surg; 2009 Oct; 50(4):861-9. PubMed ID: 19786240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention.
    Tang FK; Lin LJ; Hua N; Lu H; Qi Z; Tang XZ
    Chin Med J (Engl); 2012 Feb; 125(4):631-8. PubMed ID: 22490487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
    Kereiakes DJ; Kleiman NS; Ambrose J; Cohen M; Rodriguez S; Palabrica T; Herrmann HC; Sutton JM; Weaver WD; McKee DB; Fitzpatrick V; Sax FL
    J Am Coll Cardiol; 1996 Mar; 27(3):536-42. PubMed ID: 8606262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
    Mehta SR; Tanguay JF; Eikelboom JW; Jolly SS; Joyner CD; Granger CB; Faxon DP; Rupprecht HJ; Budaj A; Avezum A; Widimsky P; Steg PG; Bassand JP; Montalescot G; Macaya C; Di Pasquale G; Niemela K; Ajani AE; White HD; Chrolavicius S; Gao P; Fox KA; Yusuf S;
    Lancet; 2010 Oct; 376(9748):1233-43. PubMed ID: 20817281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet hyperfunction is decreased by additional aspirin loading in patients presenting with myocardial infarction on daily aspirin therapy.
    Fuchs I; Spiel AO; Frossard M; Derhaschnig U; Riedmüller E; Jilma B
    Crit Care Med; 2010 Jun; 38(6):1423-9. PubMed ID: 20400900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):612-9. PubMed ID: 19463374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
    Gremmel T; Xhelili E; Steiner S; Koppensteiner R; Kopp CW; Panzer S
    Atherosclerosis; 2014 Jan; 232(1):119-24. PubMed ID: 24401225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation.
    Van der Planken MG; Claeys MJ; Vertessen FJ; Dilling D; Bosmans JM; Berneman ZN; Michiels JJ; Vrints C
    Thromb Res; 2003; 111(3):159-64. PubMed ID: 14678814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.